$0.90
-0.06 (-6.20%)
Open$0.95
Previous Close$0.96
Day High$0.95
Day Low$0.86
52W High$3.40
52W Low$0.88
Volume—
Avg Volume113.8K
Market Cap25.23M
P/E Ratio—
EPS$-0.42
SectorBiotechnology
Analyst Ratings
Strong Sell
6 analysts
Price Target
+2,644.7% upside
Current
$0.90
$0.90
Target
$24.70
$24.70
$17.28
$24.70 avg
$43.03
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 1.17M | 1.04M | 9.21M |
| Net Income | -11,243,139 | -9,012,134 | 1.19M |
| Profit Margin | -962.1% | -914.0% | 12.9% |
| EBITDA | -9,709,254 | -8,214,990 | 1.73M |
| Free Cash Flow | — | — | 900.3K |
| Rev Growth | +12.3% | +12.3% | -0.3% |
| Debt/Equity | 1.46 | 1.46 | 0.87 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $249.46 | -0.54% | 70.2 | 443.23B |
| AMGN | Amgen Inc | $415.21 | -0.63% | 25.8 | 225.90B |
| GILD | Gilead Sciences Inc | $138.36 | +0.16% | — | 169.87B |
| VRTX | Vertex Pharmaceuticals Inc | $505.75 | -2.07% | 30.7 | 135.24B |
| REGN | Regeneron Pharmaceuticals | $803.48 | -0.31% | 19.0 | 82.16B |
| ALNY | Alnylam Pharmaceuticals Inc | $228.65 | +0.67% | 37.6 | 30.39B |